Exchange: NYSE·Updated 08:27 PM EDT
PFE logo

PFEPfizer Inc

$25.12
$0.10
(0.40%)
Today
Closed $25.15
$0.03
(0.12%)
Overnight
EarningsAug 4
Mkt Cap$143.91B
Vol30.39M
News
all
press releases
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, Pfizer) and BioNTech SE (Nasdaq: BNTX, BioNTech) announced today that the European Commission (EC) has granted marketing authorization for the companies 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by...
Business Wire
More News
Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?
MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.
Zacks
Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?
Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.
Zacks
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
SLS Stock Heads For Worst Month In Over 2 Years — But Retail Bulls ‘Hold’ For AML Readout And Buyout Hopes
An arbitrator recently dismissed Sellas’ claims against 3D Medicines and ordered about $1 million in legal-cost payments.
Stocktwits
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Pfizer (PFE) closed at $25.25, indicating a +2.35% shift from the previous trading day.
Zacks
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.
Zacks
Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.
Zacks
Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?
VRTX heads into its Q2 earnings release with Trikafta, Alyftrek, Casgevy and Journavx in focus as investors watch product sales and updates on ongoing pipeline studies.
Zacks
<
1
2
>

Advertisement|Remove ads.